Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and Compounds

Nadine Parker (PhD)[1]*, Elise Koch (PhD)[1,2], Alexey A. Shadrin (PhD)[1], Julian Fuhrer (PhD)[1], Guy F. L. Hindley (MD, PhD)[1,3], Sara E. Stinson (PhD)[1], Piotr Jaholkowski (MD, PhD)[1], Markos Tesfaye (MD, PhD)[1,4], Anders M. Dale (PhD)[5-8], Thomas S. Wingo (MD, PhD)[9], Aliza P. Wingo (MD, PhD)[10,11], Oleksandr Frei (PhD)[1,12], Kevin S. O'Connell (PhD)[1], Olav B. Smeland (MD, PhD)[1+], Ole A. Andreassen (MD, PhD)[1*+]

[1] Centre for Precision Psychiatry, University of Oslo and Oslo University Hospital, Oslo, Norway
[2] Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
[3] Department of Psychiatry, Lovisenberg Diaconal Hospital, Oslo, Norway
[4] Department of Clinical Science, University of Bergen, Bergen, Norway
[5] Multimodal Imaging Laboratory, University of California San Diego, La Jolla, CA, USA
[6] Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA,
[7] Department of Neurosciences, University of California San Diego, La Jolla, CA, USA
[8] Department of Radiology, University of California, San Diego, La Jolla, CA, USA
[9] Department of Neurology, University of California, Davis, Sacramento, CA USA
[10] Department of Psychiatry, University of California, Davis, Sacramento, CA, USA
[11] Division of Mental Health, VA Medical Center, Mather, CA, USA
[12] Department of Pharmacy, Section for Pharmacology and Pharmaceutical Biosciences, University of Oslo, Oslo, Norway

* Corresponding authors
+ These authors contributed equally.

Abstract

Genetics can inform biologically relevant drug development and repurposing which may improve patient care. Here, we leverage the genetics of psychiatric disorders to prioritize potential drug targets and compounds. We used the genome-wide association studies of four psychiatric disorders [attention deficit hyperactivity disorder (ADHD), bipolar disorder, depression, and schizophrenia] and genes encoding drug targets. We conducted drug enrichment analyses incorporating the novel and biologically specific GSA-MiXeR tool. We conducted multiple molecular trait analyses using large-scale transcriptomic and proteomic datasets sampled from brain and blood tissue. This included the novel use of the UK Biobank proteomic data for a proteome-wide association study of psychiatric disorders. With the accumulated evidence, we prioritize potential drug targets and compounds for each disorder. We reveal candidate drug targets associated with a single or multiple disorders and that implicate glutamate signalling. Drug prioritization indicated genetic support for psychotropic medications including several top ranked antipsychotics for schizophrenia. We also observed genetic support for commonly used psychotropics for psychiatric treatment (e.g., clozapine, duloxetine, and lithium). Revealed opportunities for drug repurposing included cholinergic drugs for ADHD, estrogen modulators for depression, and matrix metalloproteinases for ADHD and depression. Our findings indicate the genetic liability to schizophrenia is associated with reduced brain and blood expression of *CYP2D6,* a gene encoding a metabolizer of drugs and neurotransmitters, suggesting a genetic risk for poor drug response and altered neurotransmission. Our extensive analyses highlight the utility of genetics for informing drug development and repurposing for psychiatric disorders providing novel opportunities for improving patient outcomes.

53
Graphical Abstract. Depicted is the series of analyses conducted to generate a list of prioritized drug
targets and compounds. First pairings of genome-wide association study (GWAS) traits with drugs are
generated using enrichment analyses. Next a series of molecular trait analyses are conducted to
generate and rank list of potential drug targets for each GWAS trait. Finally, enrichment and molecular
trait results are combined to generate a ranked list of prioritized drugs for each GWAS trait based on
supporting genetic evidence. ADHD = Attention deficit hyperactivity disorder, BIP = Bipolar disorder,
DEP = Depression, SCZ = Schizophrenia, DBP = Diastolic blood pressure, T2D = Type 2 diabetes,
RNA = ribonucleic acid, XWAS = both transcriptome and proteome wide association studies, MR =
Mendelian randomization, coloc = colocalization.

Introduction

Genetics can provide insights into the underlying mechanisms of a trait that can be leveraged to inform drug development. Drugs with supporting genetic evidence have a 2.6 times greater probability of success in development compared to drugs lacking genetic support [1]. Notably, drugs for psychiatric treatment tend to have targets with less supporting genetic evidence than drugs for respiratory, metabolic, and cardiovascular diseases [1,2]. This lack of genetically informed drug development may partly explain the poor therapeutic response, adverse drug effects, and poor treatment compliance observed in psychiatry [1,3,4]. Furthermore, complex traits, such as psychiatric disorders and other medical conditions, share associated genes to a varying degree, a concept known as pleiotropy [5]. This pleiotropy may facilitate the repurposing of drugs approved or previously investigated for different indications. Therefore, leveraging genetics to inform drug discover, target prioritization, and repurposing may help improve psychiatric treatment.

The genome-wide association study (GWAS) of various psychiatric disorders have previously been leveraged to prioritize drug targets and compounds. Some studies use GWAS to perform gene-set analyses testing for enrichment of genes encoding drug targets [6–8]. While this approach has provided genetic support for various drugs with psychiatric indications, standard tools may be biased towards drugs with many targets potentially providing less disorder specificity [9]. Moreover, disorder-associated genetic variants can modulate gene expression and protein abundance providing a link to molecular traits (i.e., genes and proteins) serving as potential drug targets [10]. Therefore, transcriptome or proteome wide association studies (i.e.,

TWAS or PWAS) have been used to prioritize molecular traits as potential drug

targets for several psychiatric disorders [11,12]. Moreover, Mendelian randomization

(MR) is commonly used to identify causal relationships between molecular traits and

psychiatric disorders [13–16]. Applying these analyses has revealed for example that

calcium signalling is associated with multiple psychiatric disorders [7,11,14].

However, many studies tend to focus on one type of molecular trait or neglect

bidirectional MR analyses. Also, while transcriptomic data provides greater coverage

of the genome, drug targets are often proteins. Therefore, leveraging both types of

molecular data is complementary and more comprehensive. Although studies

leveraging multiple methodologies and types of molecular data to inform novel drug

targets and indications exist [17–21], few integrate enrichment and comprehensive

molecular trait analyses with a focus on psychiatric disorders.

Here, we present an extensive genetic interrogation of potential drug targets and

compounds for attention deficit hyperactivity disorder (ADHD), bipolar disorder (BIP),

depression (DEP), schizophrenia (SCZ) and as comparators two traits among clinical

domains with strong biological support for medication development: diastolic blood

pressure (DBP) and type 2 diabetes (T2D). We conduct gene-set analysis

incorporating the novel GSA-MiXeR tool which identifies enrichment for biologically

specific and smaller gene-sets than common approaches [9]. We use large scale

molecular trait data from brain and blood tissue to identify potential drug targets.

Blood is more readily available than brain tissue, resulting in larger datasets, and

provides complementary identification of potential drug targets. We apply a series of

molecular trait analyses including the novel use of UK Biobank (UKB) data for PWAS

of psychiatric disorders. Finally, we combine results to prioritize potential drug

targets and compounds.

Materials and Methods

Genome Wide Association Study Summary Statistics

We used summary statistics from the GWAS of four major psychiatric disorders in

European samples. For ADHD we used a GWAS containing a total of 38,691 cases

and 186,843 controls [22]. For BIP we used a GWAS including 41,917 cases and

371,549 controls [7]. For DEP we used a GWAS by Als et al. (2022) that excluded

the 23andMe sample (n_{cases}=294,322 $n_{controls}$=741,438) [23]. For SCZ we used a

GWAS including 76,755 cases and 243,649 controls [24]. As comparators, we used

GWAS summary statistics for DBP containing a total of 1,076,093 individuals [25]

and T2D containing 80,154 cases and 853,816 controls [26]. To avoid sample

overlap in analyses with the UKB proteomic samples, we used summary statistics

which excluded the UKB sample for BIP (n_{cases}=40,463, $n_{controls}$=313,436) and DEP

(n_{cases}=166,773, $n_{controls}$=507,679). GWASs conducted by the Million Veterans

Program were used for DBP (n=220,387)[27] and T2D (n=1,042,540)[28] to avoid

sample overlap with blood molecular trait datasets. We chose DBP and T2D as

comparators for several reasons: (i) DBP and T2D are not brain-related disorders

and provide a non-psychiatric comparison for our approach to drug target and

compound prioritization, (ii) in contrast to psychiatric medications, those developed

for cardiovascular and metabolic conditions have more genetic support [1,2], and (iii)

DBP is a continuous trait with summary statistics (e.g., betas) differing from the

dichotomous disorder GWAS (e.g., odds-ratio/log odds-ratio) and (iv) both DBP and

T2D have well powered publicly available GWAS summary statistics. These

differences serve to enrich the assessment of our approach.

Candidate Drug Identification

To obtain drug-target genes, we used data from the Drug Gene Interaction database

(DGIdb; https://www.dgidb.org/)[29] which collates data from 28 different sources

and is a common resource for drug enrichment analyses [6,7,30,31]. The

Supplementary Material contains data processing details.

As our primary method to test each GWAS trait (i.e., ADHD, BIP, DEP, SCZ, DBP,

T2D) for drug gene-set enrichment, we used GSA-MiXeR

(https://github.com/precimed/gsa-mixer) [9]. GSA-MiXeR models gene-level

heritability enabling the estimation of heritability partitioned across gene sets and fold

enrichment which estimates the extent to which heritability is concentrated in a given

gene set (Supplementary Material). An accompanying delta AIC value is used to

indicate model fit where a positive value suggests good model fit. Trait-drug pairs

with a positive delta AIC value were considered enriched. We additionally applied a

gene-set analysis with MAGMA [32]. While MAGMA tends to identify enrichment

among larger gene-sets than GSA-MiXeR [9], our approach requires observed

enrichment with GSA-MiXeR and nominal significance (p<0.05) with MAGMA. This

approach provides robust and potentially clinically actionable associations. All drug

gene-sets with two or more genes were included in analyses.

A list of candidate drugs for each GWAS trait was determined based on enrichment

using both GSA-MiXeR ($AIC_{delta} > 0$) and MAGMA ($p<0.05$) and ranked using fold

enrichment values from GSA-MiXeR. To assess the degree of overlapping enriched

drugs between GWAS traits, we used a hypergeometric test. Enriched drugs were

assigned an anatomic therapeutic chemical (ATC) code using classifications

released in June 2023 from BioPortal. To determine if Level 1 ATC codes were over-

represented among the candidate drugs for each GWAS trait, we used

hypergeometric tests.

Candidate Target Identification

Transcriptome- and Proteome-Wide Association Studies

To identify potential drug targets for each GWAS trait, we used the FUSION tool to

conduct a TWAS and PWAS, which we jointly refer to as XWAS [33]. For TWAS

using brain tissue, we used pre-computed single nucleotide polymorphism (SNP)

weights for 14,751 genes from the PsychENCODE sample of 1321 individuals [34].

For TWAS using blood tissue, we used pre-computed weights for 8,125 genes from

the genotype tissue expression (GTEx; n=558) resource [33,35]. For PWAS using

brain tissue, we used pre-computed weights for 2,745 proteins in 720 participants

from the Wingo et al. (2023) study [36]. For PWAS using blood tissue, we derived

our own weights for 2841 proteins in 33,239 participants from the UKB

(Supplementary Material). Since the T2D GWAS includes UKB participants, we used

precomputed weights for the atherosclerosis risk in communities (ARIC: n=7,213,

$n_{proteins}$=1,348) sample and a separate GWAS which excluded the ARIC sample [37].

We performed correction for multiple comparisons across all XWAS analyses using

the Benjamini-Hochberg method (q<0.05).

Mendelian Randomization

To further interrogate potential drug targets, we applied MR analyses using the R

package TwoSampleMR [38]. For each trait, we performed analyses using local (cis)

expression or protein quantitative trait loci (i.e., eQTL or pQTL), generally referred to

as xQTLs. We assessed both forward causal relationships (i.e., from molecular trait

to GWAS trait) and reverse causal relationships (i.e., from GWAS trait to molecular

trait). The Supplementary Material provides details on the handling of potentially

pleiotropic and proxy SNPs. Commonly, a single cis-xQTL remained after clumping

therefore, the Wald ratio MR method was used. When multiple cis-xQTLs remained

after clumping the inverse variance weighted approach was used.

From brain tissue, we used eQTL data for 18,397 genes from the MetaBrain sample

(n=6,518)[39] and pQTL data for 7,553 proteins from the Religious Orders Study

(ROS)/Rush Memory and Aging Project (MAP) sample (n=376)[40]. From blood

tissue, we used eQTL data for 19,250 genes from eQTLGen sample (n=31,684)[41]

and pQTL data for 2938 proteins from the UKB sample (n=34,090)[42]. To avoid

sample overlap between eQTLGen with DBP and T2D, we used GTEx v8 eQTL

data. In addition, to avoid sample overlap between T2D and UKB, we used the ARIC

sample. We performed correction for multiple comparisons across all MR analyses

using the Benjamini-Hochberg method (q<0.05).

Colocalization

Colocalization analyses help determine if two phenotypes share causal SNPs. For all nominally significant ($p < 0.05$) molecular trait associations, we conducted colocalization analyses with the associated GWAS trait using the R package COLOC [43]. We considered the molecular and GWAS trait colocalized when the posterior probability of colocalization was greater than 0.8 (Supplementary Material).

Prioritization of Candidate Targets

To generate a ranked list of candidate drug targets for each GWAS trait, we combined evidence across the molecular trait analyses (i.e., XWAS, MR, and colocalization). For each molecular trait analysis (e.g., brain TWAS or blood pQTL colocalization) we normalized association statistics (e.g., Z-scores or PP.H4). Normalized values were generated by dividing the absolute value of the association statistic by the sum of the absolute values across all molecular traits. The resulting normalized values fall between 0 and 1 with larger values representing stronger associations between molecular and GWAS traits. Next, for each molecular trait, the mean normalized value across all analyses, excluding missing values, was used as an overall score. Therefore, molecular traits with the strongest average GWAS associations rank highly without penalization for a lack of representation. A brain-score was generated using the mean normalized values from all brain-tissue analyses. Then, a brain-weighted score was generated as the product of the overall and brain scores. The brain-weighted score provides tissue specificity while also leveraging the large statistical power of blood tissue analyses. This final brain-weighted score was used to rank molecular traits for a given GWAS-trait. For each

GWAS trait, we performed a gene-ontology analysis of these candidate targets using

the R package clusterProfiler.

Drug Prioritization

Negative Correlation Test

We extracted drug-induced gene expression data from Connectivity Map 2020 for all

enriched drugs using the phase 2 release of the Library of Integrated Cellular

Signatures (LINCS) with the cmapR package (v 4.3.1) [44,45]. For each drug and

GWAS trait pairing, a Spearman correlation between drug induced gene expression

and variation in molecular trait associations was conducted. Negative correlations

indicate the drug may reverse changes in molecular trait abundance associated with

the GWAS trait. This "negative correlation test" was run separately for each XWAS

and MR analyses and corrections for multiple comparisons were conducted using

the Benjamini Hochberg method (q<0.05).

Prioritization of Drugs

To prioritize drugs for each GWAS trait, we calculated the mean brain-weighted

score across drug-target genes. Therefore, drugs with the strongest molecular trait

support were ranked highest. Then a final drug score was generated as the product

of the mean brain-weighted score and the normalized fold-enrichment values from

GSA-MiXeR. This final score was used to rank drugs for a given GWAS trait. If a

negative correlation test was observed for a given drug and GWAS-trait pairing, that

drug was moved one place up the ranking given the added supporting evidence.

Comparison of Drugs with Variable Efficacy

We assessed genetic support for a list of common antidepressants, antipsychotics,

mood stabilizers/anticonvulsants, and stimulants (Supplementary Material). In

addition, we assess genetic support for a selection of drugs with failed clinical trials

for medications designed to treat psychiatric disorders (Supplementary Material).

Here, we assessed the molecular trait support for each drug irrespective of whether

the drug was enriched using GSA-MiXeR.

Ethics

This study was approved by the Regional Committee for Medical Research Ethics

including the use of individual and genetics data from the UKB (accession number

27412).

Results

Drug Enrichment Analyses

We used 9,460 drug gene-sets (Supplementary Table 1) to perform enrichment

analyses. GWAS of ADHD, BIP, DEP, and SCZ were enriched for a total of 12, 107,

113, and 202 drugs using both GSA-MiXeR (n=34, 152, 283, and 295, respectively;

Supplementary Table 2) and MAGMA (n=400, 686, 566, and 713, respectively;

Supplementary Tables 3). We observed substantial overlap among the candidate

drugs for BIP and SCZ (n=63, p= 3.51e-11) but less among the other psychiatric

disorders (BIP-DEP: n=5, p=1.00, DEP-SCZ: n=13, p=1.00) and ADHD only had one

overlapping drug with DEP (Figure 1). The ATC code for nervous system drugs

(Supplementary Table 4) was enriched, for BIP (n=12/35, p=1.49e-8) and SCZ

(n=41/92, p=1.27e-21) but not ADHD (n=1/6, p=0.07) or DEP (n=7/72, p=9.65e-1).

Among the top 10 candidate drugs for BIP, DEP, and SCZ were several drugs with

antipsychotic properties (e.g., adoprazine, benperidol, cariprazine, mazapertine,

nemonapride, piperacetazine, sarizotan, and stepholidine). For ADHD, the top 10

candidate drugs were all either pro- or anti-cholinergic drugs.

As for the comparators, DBP was enriched for 257 drugs and T2D for 95 ($n_{GSA-MiXeR}$=517 and 273, respectively; n_{MAGMA}=1029 and 479, respectively; Supplementary

Tables 2 and 3). No significant overlap between candidate drugs for DBP or T2D and

the psychiatric disorders was observed (Supplementary Material Figure 1). There

was no ATC code enrichment for nervous system drugs (DPB: n=2/163, p=1.00;

T2D: n=2/43, p= 9.47e-1) but DBP had enrichment for cardiovascular system drugs

(n=80/163, p=5.86e-35) and T2D for alimentary tract and metabolism drugs

(n=21/43, p=2.42e-22).

293
Figure 1. Overlap of Enriched Drugs for Psychiatric Disorders. A network plot depicting each of
the enriched drugs (colored nodes) for each psychiatric disorder labelled central hubs. Each drug
node is colored based on their level 1 anatomical therapeutic chemical classification. Those nodes
without a color (white) represent drugs not assigned an anatomical therapeutic chemical code. The
thicker the edge (line connecting nodes to disorder), the larger the fold enrichment. ADHD = Attention
deficit hyperactivity disorder, BIP = Bipolar disorder, DEP = Depression, SCZ = Schizophrenia,
MULTIPLE = A drug with multiple classifications.
301

Molecular Trait Analyses

XWAS analyses identified 504, 1142, 1160, and 1855 significant molecular trait

associations for ADHD, BIP, DEP, SCZ, respectively (Figure 2, Supplementary Table

5). The molecular traits associated with enriched drugs are labelled in Figure 2

where several were supported by multiple XWAS analyses such as *ANKK1* with

DEP. Colocalization analyses revealed 935 (20.06%) of the significant XWAS

associations with psychiatric disorders had colocalized genetic signal

(Supplementary Tables 6) with enriched drug-target genes depicted in Figure 2 with

an asterisk. No significant negative correlation test was observed after correction for

multiple comparisons (Supplementary Table 7).

312
Figure 2. Transcriptome- and Proteome-Wide Association Study Results. For each psychiatric
disorder the results of transcriptome- and proteome-wide association studies are presented.
Significantly associated molecular traits that are also a part of gene sets for enriched drugs are labelled.
Labelled molecular traits that were also colocalized are represented with an asterisk. ADHD: attention
deficit hyperactivity disorder, BIP: bipolar disorder, DEP: Depression, SCZ: schizophrenia, TWAS =
Transcriptome wide association study, PWAS = Proteome wide association study.

Across the bidirectional MR analyses, 588, 1344, 1462, and 2421 molecular traits

were significantly associated with ADHD, BIP, DEP, and SCZ, respectively (Figure 3,

Supplementary Table 8). The molecular traits associated with enriched drugs are

labelled in Figure 3 where several were supported by multiple MR analyses such as

ADD3 with BIP and *AKT3* with SCZ. Colocalization analyses revealed 694 (11.93%)

of the significant MR associations had colocalized genetic signal (Supplementary

Tables 9) and with enriched drug-target genes depicted in Figure 3. There were no

significant negative correlation tests (Supplementary Tables 10).

DBP had 3707 significant XWAS associations and 3112 MR while T2D 1500

significant XWAS and 1799 MR associations (Supplementary Tables 5 and 8) with

many enriched drug-target genes implicated (Supplementary Material Figures 2 and

3). Colocalization was revealed for 614 (16.56%) and 330 (22.00%) XWAS as well

as 253 (8.13%) and 186 (10.34%) MR associations for DBP and T2D, respectively

(Supplementary Tables 6 and 9). No significant negative correlation test was

observed (Supplementary Tables 7 and 10).

Figure 3. Mendelian Randomization Results. For each psychiatric disorder the results of the Mendelian Randomization (MR) analyses are presented. Panel A shows the MR results in the forward direction with the psychiatric disorders as the outcome traits. Panel B shows the MR results in the reverse direction with the psychiatric disorders as the exposure traits. Significantly associated molecular traits that are also a part of a drug gene set enriched for the disorder are labelled. Labelled molecular traits that were also colocalized represented with an asterisk. ADHD: attention deficit hyperactivity disorder, BIP: bipolar disorder, DEP: Depression, SCZ: schizophrenia, eQTL = expression quantitative trait loci, pQTL = protein quantitative trait loci.

Prioritization of Potential Drug Targets and Compounds

We identified 795, 1657, 1720, and 2650 candidate drug targets supported by at

least one molecular trait analysis for ADHD, BIP, DEP, and SCZ, respectively

(Supplementary Table 11-14). Among these candidate targets, there was significant

overlap observed for BIP with SCZ (n=661, p= 1.79e-19) and DEP (n=359, p=0.02)

as well as ADHD and DEP (n=219, p= 2.39e-8). Figure 4 presents the top 10

candidate targets for each psychiatric disorder and their supporting evidence. The

gene ontology term "glutamatergic synapse" was enriched among the candidate

targets for BIP, DEP, and SCZ (Supplementary Table 17). DBP and T2D had many

candidate targets (n_{DBP}=4310, n_{T2D}=2191; Supplementary Table 15-16) and some

shared gene ontology terms with psychiatric disorders such as "glutamatergic

synapse", "MHC protein complex", and "early endosome".

After combining molecular trait support with drug enrichment for each psychiatric disorder, 2 (16.67), 67 (62.62 %), 65 (57.52%), and 116 (57.43%) drugs were supported for ADHD, BIP, DEP, and SCZ, respectively (Supplementary Table 18-21). Figure 5 presents the top 10 prioritized candidate drugs and their supporting evidence. For ADHD, a matrix metalloproteinase inhibitor and acetylcholine receptor agonist were enriched drugs with molecular trait support. For BIP, a mixture of

calcium channel blockers, protein kinase inhibitors, and drugs with

antipsychotic/antiepileptic properties were top ranked. For DEP, the top 10 drugs

included predominantly estrogen related compounds except the top two ranked

matrix metalloproteinase inhibitors. For SCZ, seven antipsychotics were among the

top 10 ranked drugs.

DBP and T2D enriched drugs had strong molecular trait support [n_{DBP}=220 (85.60%)

and n_{T2D}=64 (67.37%)] (Supplementary Table 22-23). The top 10 candidate drugs for

DBP included several approved antihypertensives (e.g., ilepatril, deserpidine, and

quinapril). For T2D, the top 10 candidate drugs included several approved for

treatment (e.g., repaglinide, mitiglinide, tolbutamide, acetohexamide, and gliclazide).

Analyses assessing molecular trait support for common psychotropics

(Supplementary Table 24) revealed: (i) common stimulants used to treat ADHD,

(e.g., methylphenidate) had no molecular trait support, (ii) DEP had molecular trait

support for several antidepressants (e.g., duloxetine, clomipramine, and citalopram)

but was never the top ranked GWAS trait, (iii) SCZ had molecular trait support and

was the top ranked GWAS trait for 10 (e.g., olanzapine, paliperidone, risperidone,

and clozapine) antipsychotics followed by BIP then DEP, (iv) BIP had support for

several mood stabilizers/anticonvulsants and was the top ranked GWAS trait for

lamotrigine (Supplementary Table 24). Among the psychotropics with failed clinical

trials (Supplementary Table 25), there was either no molecular trait support for the

outcome disorder of the trial (e.g., metadoxine for ADHD, esmethadone for DEP or

ulotaront for SCZ), or a low level of support (e.g., brexpiprazole for BIP).

Figure 5. Prioritization of Drug Compounds. The prioritized list of drug compounds (in bold) for each psychiatric disorder with molecular trait support for enriched drugs. In brackets next to each drug compound is the level 1 anatomical therapeutic chemical (ATC) classification code. Below each drug compound is a brief description. In most cases the description is based on the level 3 ATC classification. Drugs without an ATC code use descriptions from various other sources including: PubChem (PC; https://pubchem.ncbi.nlm.nih.gov/), Kyoto encyclopedia of genes and genomes (KEGG; https://www.genome.jp/kegg/kegg2.html), Therapeutic target database (TTD; https://idrblab.net/ttd/). The drug KH-CB19 is a synonym for ethyl 3-[(e)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1h-indole-2-carboxylate which is the name used in supplementary materials. nAChR = nicotinic acetylcholine receptor, MMP = Matrix metalloproteinase, DESDP = Diethylstilbestrol Diphosphate, [C] = Cardiovascular system drug, [G] = Genito urinary system and sex hormones, [N] = Nervous system drug, PKC inhib/immunosup. = Protein kinase C inhibitor and immunosuppressant.

Discussion

We prioritized potential drug targets and compounds for psychiatric disorders using

an extensive genetically informed investigation. Our approach employed novel tools

such as GSA-MiXeR [9] for drug gene-set enrichment and the novel use of UKB

proteomic data [42] for PWAS of psychiatric disorders. The series of molecular trait

analyses revealed candidate drug targets with varying degrees of overlap between

the psychiatric disorders. The prioritization of potential drugs revealed known and

investigational compounds with indications for psychiatric treatment as well as

potential opportunities for repurposing. Altogether, this work highlights the potential

utility of genetics for informing psychiatric drug development.

Top-ranked candidate targets exhibited varying degrees of overlap among the

psychiatric disorder and were consistent with previous reports. DCC was among the

top ranked candidate targets for DEP and SCZ with previous genetic links to

psychiatric disorders [24,46,47]. DCC plays a crucial role in axonal growth during

brain development including dopaminergic pathways and developmental disruptions

may result in brain structural dysconnectivity linked to various psychiatric disorders

[48–50]. Both ADHD and DEP had GPT, an enzyme involved in metabolism of

glucose and amino acids such as glutamate, among their top ranked candidate

targets which provides a potential link to energy metabolism and glutamate

associated neurotransmission. Moreover, sharing of candidate targets between BIP,

DEP, and SCZ revealed enrichment for the gene ontology term "excitatory

glutamatergic synapse" providing further support for glutamate signalling as a

therapeutic target for psychiatric disorders and suggests the need for more

therapeutic investigations of glutamate signalling in psychiatry [51,52]. Meanwhile,

we and others [12,53] have linked B3GLCT to DEP and since we found only BIP was

also associated, B3GLCT may be mood disorder specific. While these findings

require further investigation of a wider variety of disorders, revealing potential drug

targets specific to a subclass of disorders can be useful for targeting similar cross-

disorder symptomology or commonly co-morbid disorders. Many of our top ranked

candidate targets have been previously linked to their associated psychiatric

disorders in the original GWAS or through various molecular trait analyses.

Examples of these associations include: PPP1R16A and LSM6A with ADHD [22];

CNNM2, CTNND1, and MKRN1 with DEP [12,23,54]; PDF, PRKCB, and ABCB8

with BIP [54]; ASPHD1, DCC, CNNM2, and CYP7B1 with SCZ [24,54]. The

consistency across reports further strengthens the support for the prioritized

candidate targets.

Consistent with previous studies, our results provide genetic support for drugs with

known or putative indications for psychiatric treatment [6,7,11,31]. In particular, the

top 10 prioritized drugs for SCZ included 7 antipsychotics. In addition, we find that

drugs with failed clinical trials either have no molecular trait support for their

indicated disorder or were ranked low on the list of prioritized drugs. These findings

help validate our approach for prioritizing drugs. However, our findings also reveal a

lack of genetic support for stimulants for treating ADHD [55]. Notably, ADHD had the

lowest drug enrichment and molecular trait associations which likely reflect the lower

power of the GWAS compared to the other psychiatric traits. Therefore, with future

larger GWAS, a clearer picture of the genetic architecture of psychiatric disorders will

be revealed and can be further leveraged to inform drug development.

Identified drugs in our study additionally highlight opportunities for repurposing. The

majority of enriched drugs for ADHD modulate acetylcholine receptors and one

agonist (CP-601927) had candidate target support, which is in line with the

previously proposed use of cholinergic drugs for ADHD treatment [56]. Top ranked

drugs for ADHD and DEP included matrix metalloproteinase (MMP) inhibitors which

have been proposed as a new avenue for drug development and repurposing in

psychiatrics [57]. MMPs are involved in synaptic remodelling and inflammatory

responses in the brain and have been linked to various psychiatric disorders [57].

After MMP inhibitors, the top ranked drugs for DEP were predominantly estrogen

modulators which have previously been linked to DEP but are not currently indicated

treatment [58–60]. While estrogen is a female sex hormone it's modulation as a

putative therapeutic target may be relevant for both males and females [61–63].

More work is needed to understand the sex-specific genetic support for psychiatric

drug development where sex-stratified analyses are critical.

Combining enrichment with molecular trait analyses revealed important clinical

implications for enriched drug targets. Across several analyses and consistent with

previous reports, genetic liability to SCZ was associated with reduced expression of

CYP2D6, an enriched drug target that plays a role in metabolism of

neurotransmitters and drugs, including antipsychotics [14,64–66]. Therefore, lower

levels of *CYP2D6* may contribute to SCZ pathophysiology and also disrupt treatment

response which supports efforts for therapeutic monitoring of *CYP2D6*

polymorphisms and evidence-based drug dosing [14,67]. ANKK1 was negatively

associated with DEP in several analyses, includes a polymorphism linked to

reductions in dopamine receptor abundance, and is a target for several psychotropic

drugs [68,69]. Therefore, while many antipsychotics have high affinity for both

dopamine and serotonin receptors [70], ANKK1 may be an alternative link for

response to antipsychotics in patients with DEP. Consistent with previous reports,

BIP and SCZ were associated with candidate targets related to cellular calcium

supporting the prioritization of calcium channel blockers for BIP and their continued

investigation as therapeutic drugs in psychiatry [7,14,71]. Altogether, these current

drug targets revealed important implications for drug development.

This study has several strengths and limitations. Using DBP and T2D as

comparators revealed a lack of overlap in candidate drug targets and enriched drug

compounds with any psychiatric disorder and showed the generalizability of our

approach beyond psychiatric disorders. A limitation to our MR analyses is the

potential for weak instrument bias particularly when using a single instrument

approach. This may bias results towards the null leading to a failure to detect true

relationships between molecular traits and GWAS traits [38]. Our approach

prioritizes drugs irrespective of effect direction. Therefore, we identify drugs with

genetic evidence for beneficial or detrimental effects for a trait. While this is useful,

our findings require careful interpretation and further investigation. We also use

transcriptomic and proteomic data from both brain and blood tissue. The molecular

traits and tissue sources are complimentary but not completely correlated.

Nevertheless, their integration improves the power to identify modifiable drug targets

[72,73]. Our findings may lack generalizability beyond individuals of European

ancestry due in part to the reliance of tools on European references and a lack of

well powered non-European GWASs and sources of molecular trait data.

Additionally, the power of the included GWAS traits vary, which likely contributes to

greater drug enrichment and molecular support for GWAS traits with higher power

(i.e., SCZ and DBP) compared to those with lower power (i.e., ADHD). This power

discrepancy also effects the observed overlap across GWAS traits.

In conclusion, our extensive analytical approach leveraged psychiatric GWAS

combined with novel tools and molecular trait data to prioritize potential drug targets

and compounds. The candidate targets can be used for future development of

psychotropics. Meanwhile, the prioritized drugs can be used for future repurposing

efforts. This study provides clinically relevant evidence for how psychiatric genetics

can inform future drug development and repurposing with the potential to improve

patient outcomes.

Data Availability Statement

All GWAS summary statistics and molecular trait data included in this study are

publicly available. We generated PWAS weights using proteomic data from the UK

Biobank and have shared those weights on figshare

[https://doi.org/10.6084/m9.figshare.31487881]. The GWAS summary statistics from

the Million Veteran Program were downloaded from the dbGaP web site, under

accession phs001672.

References

1. Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on clinical success. Nature. 2024:1–6.

2. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–860.

3. Linden M, Schermuly-Haupt M-L. Definition, assessment and rate of psychotherapy side effects. World Psychiatry. 2014;13:306–309.

4. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119–136.

5. Solovieff N, Cotsapas C, Lee PH, Purcell SM, Smoller JW. Pleiotropy in complex traits: challenges and strategies. Nat Rev Genet. 2013;14:483–495.

6. Bell N, Uffelmann E, Walree E van, Leeuw C de, Posthuma D. Using genome-wide association results to identify drug repurposing candidates. 2022:2022.09.06.22279660.

7. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021;53:817–829.

8. O'Connell KS, Koromina M, Veen T van der, Boltz T, David FS, Yang JM, et al. Genomics yields biological and phenotypic insights into bipolar disorder. 2024:2023.10.07.23296687.

9. Frei O, Hindley G, Shadrin AA, van der Meer D, Akdeniz BC, Hagen E, et al. Improved functional mapping of complex trait heritability with GSA-MiXeR implicates biologically specific gene sets. Nat Genet. 2024;56:1310–1318.

10. Reay WR, Cairns MJ. Advancing the use of genome-wide association studies for drug repurposing. Nat Rev Genet. 2021;22:658–671.

11. Grotzinger AD, Fuente J de la, Davies G, Nivard MG, Tucker-Drob EM. Transcriptome-wide and Stratified Genomic Structural Equation Modeling Identify Neurobiological Pathways Underlying General and Specific Cognitive Functions. 2021.

12. Wingo TS, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, et al. Brain proteome-wide association study implicates novel proteins in depression pathogenesis. Nat Neurosci. 2021;24:810–817.

13. Li X, Shen A, Zhao Y, Xia J. Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders. Schizophrenia Bulletin. 2023;49:1305–1315.

14. Liu J, Cheng Y, Li M, Zhang Z, Li T, Luo X-J. Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders. Neuropsychopharmacol. 2023;48:270–280.

15. Deng Y-T, Ou Y-N, Wu B-S, Yang Y-X, Jiang Y, Huang Y-Y, et al. Identifying causal genes for depression via integration of the proteome and transcriptome from brain and blood. Mol Psychiatry. 2022;27:2849–2857.

16. Lu T, Forgetta V, Greenwood CMT, Zhou S, Richards JB. Circulating Proteins Influencing Psychiatric Disease: A Mendelian Randomization Study. Biological Psychiatry. 2023;93:82–91.

17. Namba S, Konuma T, Wu K-H, Zhou W, Okada Y. A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. Cell Genomics. 2022;2:100190.

18. Sadler MC, Auwerx C, Deelen P, Kutalik Z. Multi-layered genetic approaches to identify approved drug targets. Cell Genomics. 2023;3:100341.

19.   Reay WR, Geaghan MP, Atkins JR, Carr VJ, Green MJ, Cairns MJ. Genetics-informed
precision treatment formulation in schizophrenia and bipolar disorder. The American
Journal of Human Genetics. 2022;109:1620–1637.
20.   Koscielny G, An P, Carvalho-Silva D, Cham JA, Fumis L, Gasparyan R, et al. Open
Targets: a platform for therapeutic target identification and validation. Nucleic Acids
Research. 2017;45:D985–D994.
21.   Koch E, Kauppi K, Chen C-H. Candidates for drug repurposing to address the cognitive
symptoms in schizophrenia. Progress in Neuro-Psychopharmacology and Biological
Psychiatry. 2023;120:110637.
22.   Demontis D, Walters GB, Athanasiadis G, Walters R, Therrien K, Nielsen TT, et al.
Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture
and implicate several cognitive domains. Nat Genet. 2023;55:198–208.
23.   Als TD, Kurki MI, Grove J, Voloudakis G, Therrien K, Tasanko E, et al. Depression
pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using
genome-wide analyses. Nat Med. 2023;29:1832–1844.
24.   Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al.
Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature.
2022;604:502–508.
25.   Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al.
Genetic analysis of over 1 million people identifies 535 new loci associated with blood
pressure traits. Nat Genet. 2018;50:1412–1425.
26.   Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, et al. Multi-
ancestry genetic study of type 2 diabetes highlights the power of diverse populations for
discovery and translation. Nat Genet. 2022;54:560–572.
27.   Giri A, Hellwege JN, Keaton JM, Park J, Qiu C, Warren HR, et al. Trans-ethnic
association study of blood pressure determinants in over 750,000 individuals. Nat
Genet. 2019;51:51–62.
28.   Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, et al. Discovery
of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4
million participants in a multi-ancestry meta-analysis. Nat Genet. 2020;52:680–691.
29.   Cannon M, Stevenson J, Stahl K, Basu R, Coffman A, Kiwala S, et al. DGIdb 5.0:
rebuilding the drug–gene interaction database for precision medicine and drug discovery
platforms. Nucleic Acids Research. 2024;52:D1227–D1235.
30.   Cheng W, Parker N, Karadag N, Koch E, Hindley G, Icick R, et al. The relationship
between cannabis use, schizophrenia, and bipolar disorder: a genetically informed study.
The Lancet Psychiatry. 2023;10:441–451.
31.   Bipolar Disorder Working Group of the Psychiatric Genomics Consortium 23andMe
Research Team, O'Connell KS, Koromina M, Forstner AJ, McQuillin A, Florio AD, et
al. Genetic diversity enhances gene discovery for bipolar disorder.
2023:2023.10.07.23296687.
32.   De Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set
Analysis of GWAS Data. PLoS Comput Biol. 2015;11:1004219–1004219.
33.   Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BWJH, et al. Integrative
approaches for large-scale transcriptome-wide association studies. Nat Genet.
2016;48:245–252.
34.   Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, et al. Transcriptome-
wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science.
2018;362.

35. Ardlie KG, DeLuca DS, Segrè AV, Sullivan TJ, Young TR, Gelfand ET, et al. The
Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in
humans. Science. 2015;348:648–660.

36. Wingo AP, Liu Y, Gerasimov ES, Vattathil SM, Liu J, Cutler DJ, et al. Sex differences
in brain protein expression and disease. Nat Med. 2023;29:2224–2232.

37. Zhang J, Dutta D, Köttgen A, Tin A, Schlosser P, Grams ME, et al. Plasma proteome
analyses in individuals of European and African ancestry identify cis-pQTLs and
models for proteome-wide association studies. Nat Genet. 2022;54:593–602.

38. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base
platform supports systematic causal inference across the human phenome. eLife.
2018;7:e34408.

39. de Klein N, Tsai EA, Vochteloo M, Baird D, Huang Y, Chen C-Y, et al. Brain
expression quantitative trait locus and network analyses reveal downstream effects and
putative drivers for brain-related diseases. Nat Genet. 2023;1–12.

40. Wingo AP, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, et al.
Integrating human brain proteomes with genome-wide association data implicates new
proteins in Alzheimer's disease pathogenesis. Nat Genet. 2021;53:143–146.

41. Võsa U, Claringbould A, Westra H-J, Bonder MJ, Deelen P, Zeng B, et al. Large-scale
cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores
that regulate blood gene expression. Nat Genet. 2021;53:1300–1310.

42. Sun BB, Chiou J, Traylor M, Benner C, Hsu Y-H, Richardson TG, et al. Plasma
proteomic associations with genetics and health in the UK Biobank. Nature.
2023;622:329–338.

43. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.
Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using
Summary Statistics. PLOS Genetics. 2014;10:e1004383.

44. Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A Next
Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell.
2017;171:1437-1452.e17.

45. Enache OM, Lahr DL, Natoli TE, Litichevskiy L, Wadden D, Flynn C, et al. The GCTx
format and cmap{Py, R, M, J} packages: resources for optimized storage and integrated
traversal of annotated dense matrices. Bioinformatics. 2019;35:1427–1429.

46. Lee PH, Anttila V, Won H, Feng Y-CA, Rosenthal J, Zhu Z, et al. Genomic
Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric
Disorders. Cell. 2019;179:1469-1482.e11.

47. Smeland OB, Wang Y, Frei O, Li W, Hibar DP, Franke B, et al. Genetic Overlap
Between Schizophrenia and Volumes of Hippocampus, Putamen, and Intracranial
Volume Indicates Shared Molecular Genetic Mechanisms. Schizophrenia Bulletin.
2018;44:854–864.

48. Vosberg DE, Leyton M, Flores C. The Netrin-1/DCC guidance system: dopamine
pathway maturation and psychiatric disorders emerging in adolescence. Mol Psychiatry.
2020;25:297–307.

49. Parker N, Cheng W, Hindley GFL, Parekh P, Shadrin AA, Maximov II, et al.
Psychiatric disorders and brain white matter exhibit genetic overlap implicating
developmental and neural cell biology. Mol Psychiatry. 2023;1–9.

50. Repple J, Gruber M, Mauritz M, de Lange SC, Winter NR, Opel N, et al. Shared and
Specific Patterns of Structural Brain Connectivity Across Affective and Psychotic
Disorders. Biological Psychiatry. 2023;93:178–186.

51. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry.
2004;9:984–997.

52. Leucht S, Siafis S, McGrath JJ, McGorry P, Howes OD, Tamminga C, et al.
Schizophrenia. Nat Rev Dis Primers. 2025;11:83.
53. Howard DM, Adams MJ, Shirali M, Clarke T-K, Marioni RE, Davies G, et al. Genome-
wide association study of depression phenotypes in UK Biobank identifies variants in
excitatory synaptic pathways. Nat Commun. 2018;9:1470.
54. Wingo AP, Liu Y, Vattathil SM, Gerasimov ES, Mei Z, Ravindran SP, et al.
Multiancestry brain pQTL fine-mapping and integration with genome-wide association
studies of 21 neurologic and psychiatric conditions. Nat Genet. 2025;57:2156–2165.
55. Quintero J, Gutiérrez-Casares JR, Álamo C. Molecular Characterisation of the
Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on
ADHD Neurobiology: A Review. Neurol Ther. 2022;11:1489–1517.
56. Potter AS, Schaubhut G, Shipman M. Targeting the Nicotinic Cholinergic System to
Treat Attention-Deficit/Hyperactivity Disorder: Rationale and Progress to Date. CNS
Drugs. 2014;28:1103–1113.
57. Kaczmarek KT, Protokowicz K, Kaczmarek L. Matrix metalloproteinase-9: A magic
drug target in neuropsychiatry? Journal of Neurochemistry. 2024;168:1842–1853.
58. Adams MJ, Streit F, Meng X, Awasthi S, Adey BN, Choi KW, et al. Trans-ancestry
genome-wide study of depression identifies 697 associations implicating cell types and
pharmacotherapies. Cell. 2025;188:640-652.e9.
59. de Novaes Soares C, Almeida OP, Joffe H, Cohen LS. Efficacy of Estradiol for the
Treatment of Depressive Disorders in Perimenopausal Women: A Double-blind,
Randomized, Placebo-Controlled Trial. Archives of General Psychiatry. 2001;58:529–
534.
60. Lorsch ZS, Loh Y-HE, Purushothaman I, Walker DM, Parise EM, Salery M, et al.
Estrogen receptor α drives pro-resilient transcription in mouse models of depression.
Nat Commun. 2018;9:1116.
61. Stanikova D, Luck T, Bae YJ, Thiery J, Ceglarek U, Engel C, et al. Increased estrogen
level can be associated with depression in males. Psychoneuroendocrinology.
2018;87:196–203.
62. Carrier N, Saland SK, Duclot F, He H, Mercer R, Kabbaj M. The Anxiolytic and
Antidepressant-like Effects of Testosterone and Estrogen in Gonadectomized Male Rats.
Biological Psychiatry. 2015;78:259–269.
63. Albert KM, Newhouse PA. Estrogen, Stress, and Depression: Cognitive and Biological
Interactions. Annual Review of Clinical Psychology. 2019;15:399–423.
64. Bertilsson L, Dahl M-L, Dalén P, Al-Shurbaji A. Molecular genetics of CYP2D6:
Clinical relevance with focus on psychotropic drugs. British Journal of Clinical
Pharmacology. 2002;53:111–122.
65. Ma L, Shcherbina A, Chetty S. Variations and expression features of CYP2D6
contribute to schizophrenia risk. Mol Psychiatry. 2021;26:2605–2615.
66. Wang X, Li J, Dong G, Yue J. The endogenous substrates of brain CYP2D. European
Journal of Pharmacology. 2014;724:211–218.
67. Milosavljević F, Bukvić N, Pavlović Z, Miljević Č, Pešić V, Molden E, et al.
Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With
Antidepressant and Antipsychotic Exposure. JAMA Psychiatry. 2021;78:1–11.
68. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1:
A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human
Mutation. 2004;23:540–545.
69. Suzuki A, Mihara K, Kondo T, Tanaka O, Nagashima U, Otani K, et al. The relationship
between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic

724   response to nemonapride, a selective dopamine antagonist, in schizophrenic patients.
725   Pharmacogenetics and Genomics. 2000;10:335.

726 70. Meltzer HY. The Role of Serotonin in Antipsychotic Drug Action.
727   Neuropsychopharmacol. 1999;21:106–115.

728 71. Cipriani A, Saunders K, Attenburrow M-J, Stefaniak J, Panchal P, Stockton S, et al. A
729   systematic review of calcium channel antagonists in bipolar disorder and some
730   considerations for their future development. Mol Psychiatry. 2016;21:1324–1332.

731 72. Manzoni C, Kia DA, Vandrovcova J, Hardy J, Wood NW, Lewis PA, et al. Genome,
732   transcriptome and proteome: the rise of omics data and their integration in biomedical
733   sciences. Briefings in Bioinformatics. 2018;19:286–302.

734 73. Qi T, Wu Y, Zeng J, Zhang F, Xue A, Jiang L, et al. Identifying gene targets for brain-
735   related traits using transcriptomic and methylomic data from blood. Nat Commun.
736   2018;9:2282.

Acknowledgments

We thank all participants, staff, and providers of the publicly available data used in this study including individuals from the UKB, psychiatric genomics consortium, Million Veterans Program, PsychENCODE, ARIC, MetaBrain, ROS/MAP, eQTLGen, GTEx.

Author Contributions

NP and OBS conceived of the study and EK, AAS, GFLH, SS, PJ, KSO, and OAA were involved in study design. NP, EK, AAS, TSW, and APW were involved in data acquisition and processing. NP, EK, AAS, and JF were involved in data analysis. NP had access to all data and drafted the initial manuscript. All authors contributed to data interpretation and editing of the manuscript and accepted responsibility to submit the manuscript for publication.

Funding

Funding was provided by the US National Institutes of Health (grants U24DA041123, R01AG076838, U24DA055330, OT2HL161847 and 5R01MH124839-02), the Research Council of Norway (grants 296030, 273291, 273446, 300309, 324252, 326813, 334920), the South-East Regional Health Authority (grant 2022–073), EEA-RO-NO-2018–0573, EEA-RO-NO-2018–0535, EU's Horizon 2020 Research and Innovation Programme (grant 847776; CoMorMent and 964874 REALMENT), Novo Nordisk Foundation (grant NNF23OC0099658), the Marie Skłodowska-Curie Actions Grant 801133 (Scientia fellowship). This work was performed on Services for sensitive data (TSD), University of Oslo, Norway, with resources provided by

Competing Interest

OAA has received speaker fees from Lundbeck, Janssen, Otsuka, and Sunovion and

is a consultant to Cortechs.ai. and Precision Health. AMD is Founding Director, holds

equity in CorTechs Labs, Inc. (DBA Cortechs.ai), and serves on its Board of

Directors and the Scientific Advisory Board. He is an unpaid consultant for Oslo

University Hospital. The terms of these arrangements have been reviewed and

approved by the University of California, San Diego in accordance with its conflict-of-

interest policies. OF is a consultant to Precision Health. TSW is a co-founder of

revXon, which is disclosed and approved to University of California, Davis per its

conflict-of-interest policy. All other authors report no biomedical financial interests or

potential conflicts of interest.